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Abstract
Dilated cardiomyopathy is the most common form of cardiomyopathy and the 
second leading cause of left ventricular dysfunction with highly variable clinical 
presentation and prognosis. The clinical courses vary and are strongly heteroge-
neous, ranging from asymptomatic patients to those suffering from intractable 
heart failure or sudden cardiac death due to arrhythmias. Previous studies have 
reported a 10 years cardiovascular mortality up to 40% in developed countries, 
due to advanced heart failure or sudden cardiac death. However, the prognosis of 
dilated cardiomyopathy patients is variable and depends on multiple risk factors. 
This chapter provides a review of dilated cardiomyopathy with specific focus on the 
pathophysiological aspects and genetic etiology of the disease.
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1. Introduction
Dilated cardiomyopathy (DCM) is one of the most common cardiomyopathies 
causing heart failure (HF) worldwide. Although it is less common than coronary 
artery disease (CAD), it affects mainly young adults and presents the most frequent 
reason for cardiac transplantation in young age [1, 2]. According to the European 
Society of Cardiology (ESC), the current definition of DCM includes the presence 
of a dilated and poorly functioning left ventricle or of both ventricles [3]. A het-
erogeneous group of myocardial and systemic conditions may cause left ventricular 
dilatation in combination with dysfunction. In fact, identifying the etiology of 
DCM can be very challenging, which often leads to the common terminology of 
idiopathic dilated cardiomyopathy (IDC). Furthermore, DCM has a highly variable 
clinical presentation. While signs and symptoms of HF are most common, some 
patients are incidentally, for instance, by diagnosing cardiomegaly in chest X-ray. 
Other symptoms include arrhythmias, conduction disturbances, thromboembolic 
complications, or sudden cardiac death (SCD). In the last decades, major advances 
have been made in the understanding of molecular and genetic issues, as well as 
in the pathophysiology and clinical assessment of cardiomyopathies. Especially, 
understanding the genetic basis of DCM has improved considerably with the 
availability of genetic analysis. In addition, other important diagnostic approaches, 
particularly imaging methods are more widely available. This allows early diagnosis 
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and the initiation of adequate therapy, which already has led to an improvement of 
the prognosis in the last years. Data have shown that approximately 25% of DCM 
patients with recent onset of HF (<6 months) have ameliorated in symptoms or 
even have complete cardiac function recovery [4, 5]. However, the overall prognosis 
in patients with symptomatic HF and DCM is still poor. In order to further improve 
the prognosis of our patients, it is important to regularly gather the knowledge 
about the current state of DCM and adapt the appropriate diagnostic workups. 
Therefore, this chapter provides the reader with a comprehensive overview of the 
current state of DCM from definition over etiology including the genetics aspects to 
management for cardiovascular specialists.
2. Dilated cardiomyopathy: a frequent cardiac disease
2.1 Definition
In 1980, the World Health Organization (WHO) defined cardiomyopathies as 
“heart muscle diseases of unknown cause” [6]. The definition was established to 
distinguish cardiomyopathies from cardiac diseases with known entities such as 
hypertension, ischemic, or valvular heart disease. About 15 years later, the WHO/
International Society and Federation of Cardiology (ISFC) Task Force classified 
cardiomyopathies according to anatomy and physiology into dilated cardiomyopa-
thy (DCM), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy 
(RCM), arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) 
and unclassified cardiomyopathies. The definitions and classifications of cardiomy-
opathies changed over the years. The American Heart Association (AHA) presented 
a new scheme in 2006 that combined genetic and clinical criteria [7]. In contrast to 
that, the ESC defined in 2008 cardiomyopathies in a more clinically oriented classi-
fication system according to the WHO scheme as myocardial disorders with struc-
turally and functionally abnormities of the heart muscle in the absence of coronary 
artery disease, hypertension, valvular disease, or congenital heart disease [3]. As 
mentioned above, right ventricular dilatation and dysfunction may be present but 
are not necessary for the diagnosis. Further, DCM is classified into familial/genetic 
and nonfamilial/nongenetic forms [3]. Recently, a revised definition of DCM was 
presented by the ESC working group on myocardial and pericardial diseases [8]. 
This position paper did not modify the above-mentioned definition, it rather added 
the important value of diverse etiologies and clinical manifestations with an intro-
duction of a novel concept of a continuous phenotypic DCM spectrum, ranging 
from the subclinical mutation carriers to fully expressed DCM phenotypes.
2.2 Prevalence
The prevalence of DCM in the general population is unknown. The reported 
numbers considerably vary due to inhomogeneous study methodologies, which are 
mainly related to inconsistent definitions and classifications of DCM. In addition, 
the prevalence of DCM varies according to geographic and ethnic differences. 
One of the first reports was derived from an epidemiological study conducted in 
Olmsted County, Minnesota, from 1975 to 1984. For the diagnosis of DCM, the 
authors implemented echocardiography, angiography, and autopsy cases [9]. They 
presented a prevalence of 36.5/100,000 individuals or 1 in 2700 with a male to 
female ratio of 3:4 in a European-American population. A much higher prevalence 
with 1:250 was reported recently by a study from Hershberger et al. The authors 
estimated the DCM prevalence based on the known ratio of idiopathic DCM to 
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HCM of ≈2:1. In addition, clinical data of HF patients and left ventricular dysfunc-
tion were used as a surrogate for DCM [10]. In Western countries, 25–40% of DCM 
patients have been described with evidence of familial DCM with predominantly 
autosomal dominant inheritance [4, 11–13]. In general, epidemiologic studies 
have stated a rate of 20 up to >50% of familial DCM in patients, who were initially 
diagnosed with IDC [9, 11, 14–18].
2.3 Clinical presentation
The first presentation of patients with DCM is often characterized by signs and 
symptoms of HF, such as dyspnea, ankle swelling, fatigue, elevated jugular venous 
pressure, pulmonary rales, and peripheral edema (Table 1). These result from 
reduced cardiac function with low output and/or elevated intracardiac pressures. 
Other clinical manifestations include chest pain caused by reduced coronary blood 
flow or congestion, palpitations, and syncope or sudden cardiac death (SCD). 
Arrhythmia results from multifactorial reasons, which are present in DCM and 
include structural changes with myocardial fibrosis and left ventricular dilation as 
well as electrophysiological changes [19]. The risk of SCD is highly heterogeneous 
and depends on etiologies and risk factors [20]. Some genetic constellations may 
be associated with arrhythmias out of proportion to the degree of left ventricular 
dysfunction (e.g., pathogenic variants in DES, LMNA, and SCN5A) [21]. This is 
described later in this chapter (see Sections 2.7.3 and 2.8). Furthermore, patients 
might present with pulmonary and systemic thromboembolism [22]. Possible clini-
cal findings are summarized in Table 1.
Cardiac Pulmonary Gastrointestinal/
urogenital
Other
Symptoms Chest pain
Palpitations
Syncope
Dyspnea
Wheeze
Blood-tinged 
sputum
Cough
Reduced appetite
Epigastral pain
Bloating
Obstipation
Diarrhea
Swollen abdomen
Nycturia
Reduced libido
Erectile dysfunction
Dizziness
Lightheadness
Concentration disturbances
Fatigue
Fainting
Sweating
Leg swelling
Symptoms of multisystem 
disease
Skin alterations
Visual and hearing 
impairment
Gait disturbance
Clinical signs Hypotonia
Tachycardia
Pulsus alternans
Arrhythmia
Third heart 
sound
Loud 2nd heart 
sound
Displaced apex 
beat
Elevated jugular 
venous pressure
Eedema
Tachycardia
Tachypnoea
Low oxygen 
saturation
Hemoptysis
Rales
Obstructive lung 
auscultation
Diminished lung 
sounds due to 
pleural effusions
Pulmonary edema
Hepatomegaly
Ascites
Jaundice in terminal liver 
failure
Cachexia
Intellectual disability
Deafness
Myotonia
Hyperpigmentation
Palmoplantar keratoderma
Woolly hair
Dysmorphic appearance
Polyneuropathic symptoms
Carpal tunnel syndrome
Table 1. 
Clinical findings in dilated cardiomyopathy.
Visions of Cardiomyocyte - Fundamental Concepts of Heart Life and Disease
4
2.4 Pathophysiological aspects and etiology
As a consequence of the definition, the etiology of left ventricular dilatation 
and dysfunction is heterogeneous. In developed countries, CAD is the most com-
mon cause of left ventricular dilatation and dysfunction, and responsible for 
approximately 50–70% of HF patients. Therefore, potentially reversible myocardial 
ischemia must always be excluded for the diagnosis of DCM. The following section 
describes in detail the possible causes of the DCM (Figure 1). However, the current 
literature underscores that the cause of DCM remains unknown, that is, IDC, in 
half of the patients [23].
2.4.1 Non-genetic causes of DCM
2.4.1.1 Inflammatory cardiomyopathy
DCM can occur after a cardiac infection or inflammation as an early (e.g. giant-
cell myocarditis) or late stage disease. Typically, the active or fulminant myocarditis 
appears with preserved left ventricular size, while in contrast inflammatory DCM 
is defined as the presence of chronic inflammatory cells in association with left 
ventricular dilatation and reduced fraction [3]. The inflammatory myocarditis can 
result from an infection or may be mediated by autoimmune mechanisms. The 
infectious myocarditis is commonly caused by viral pathogens as an acute or chronic 
disease [24]. In the developed countries until the 1990s, the most frequently reported 
viruses were adenoviruses and enteroviruses. Recently, parvovirus B12 and human 
herpes virus-6 are increasingly reported causing DCM [25]. In the acute phase, 
the virus replicates actively within the myocardium. This leads to dysfunction of 
cardiomyocytes and endothelial cells, and thus triggering the immune response [23]. 
Commonly, the innate immune system clears the viral load whereas insufficient 
immune response results in viral persistence and progressive myocyte destruction 
[25]. The secondary effect is triggered by primed T-cells. In addition, some host 
myocardial cellular antigens may share epitopic similarities with viral antigens and 
induce an autoimmune response with further destruction of cardiomyocytes [23]. 
Figure 1. 
Etiologies of the dilated cardiomyopathy.
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Another important viral-related form of DCM is HIV syndrome. DCM in HIV 
patients is called HIV-associated cardiomyopathy. Autopsies demonstrated histologi-
cal evidence of myocarditis in around 50% of patients, who died of AIDS-related 
illness [26]. Bacterial infections such as brucellosis, diphtheria, psittacosis, and 
typhoid fever are also known to cause (peri-) myocarditis [27–30]. In addition, E. coli 
bacteraemia have been described to induce myocarditis [31]. Spirochaetal myocardi-
tis may be encountered in the setting of the Lyme disease (Borrelia burgdorferi), the 
Weil disease (Leptospirosis), and syphilis (Treponema pallidum) [32]. In endemic 
areas, the protozoan parasite Trypanosoma cruzi is a typical cause of DCM due to 
acute cardiac infection (perimyocarditis), as well as chronic myocardial fibrosis 
leading to DCM [33]. There are several proposed mechanisms leading to DCM in 
autoimmune disorders. These include immune-mediated myocarditis, progressive 
fibrosis, apoptosis with resultant restrictive and dilated phenotypes, and progressive 
atherosclerosis with subsequent ischemic cardiomyopathy [26]. Other causes for a 
non-infectious myocarditis are: Kawasaki disease in children with coronary vascu-
litis and systemic lupus erythematosus, which can affect the myocardium without 
involvement of the pericardium. In rare cases, connective tissue diseases such as 
scleroderma, rheumatoid arthritis, and polyarteritis nodosa may lead to DCM [26]. 
The non-infectious etiologies of myocarditis include drug-induced hypersensitivity 
and hypereosinophilic syndromes, as well as giant-cell myocarditis, which is one of 
the most aggressive non-infectious autoimmune disorders with rapid and devastating 
outcome if not treated appropriately [24, 26].
2.4.1.2 Peripartum cardiomyopathy
Peripartum cardiomyopathy (PPCM) affects predisposed teenagers and older 
women during the last month of pregnancy or within 5 months of delivery with 
typical signs and symptoms of HF [34, 35]. Suspected etiological factors include 
inflammatory myocarditis, autoimmunity caused by chimerism of hematopoietic 
lineage cells from the fetus, hemodynamic stress during pregnancy, and toxicity 
caused by an abnormal cleavage product of prolactin [3, 36]. Furthermore, genetic 
predisposition seems to be important [37].
2.4.1.3 Toxic cardiomyopathies
A number of chemical compounds are responsible for DCM. In western and 
developing countries, alcoholic cardiomyopathy (ACM) represents one of the most 
common forms of secondary cardiomyopathies resembling IDC with an estimated 
prevalence of 23–40% [24, 38]. More than women, men are affected by ACM and 
the occurrence correlates with a daily level and the duration of alcohol consump-
tion [39]. However, the prevalence of ACM is variable and the mean daily amount 
of alcohol consumption, duration of regular intake, and patients’ individual 
characteristics, including genetic susceptibility, are all related to the development 
of a respective cardiomyopathy [26]. Alcohol may result in both acute and chronic 
depression of myocardial contractility. Street drugs such as cocaine and metham-
phetamines are potent sympathomimetic drugs that induce inotropic and chrono-
tropic effects. Mechanisms of cardiac toxicity include myocardial ischemia from 
increased oxygen consumption, prothrombotic effects, coronary vasospasms, and 
acceleration of coronary atherosclerosis [24]. Anthracycline-based chemothera-
peutic agents are known to induce cardiac dysfunction. Acute or subacute injury 
can occur immediately after treatment with transient arrhythmias, pericarditis, 
and myocarditis [38]. The time course of chronic development of HF varies from an 
early onset (<1 year) to late onset (>1 year) or chronic progressive cardiomyopathy, 
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which can occur 10–30 years after exposure. Both chronic forms tend to be irre-
versible, are dosage dependent and are associated with ultrastructural changes in 
the cardiac myocytes [40]. Trastuzumab, a monoclonal antibody directed against 
the human epidermal growth factor receptor 2 (HER2), is wildly used and very 
effective for the treatment of HER2-positive breast cancer. HER2 receptors are also 
localized on the cardiomyocyte. The inhibition of the Her2:Her4 signaling process 
in the myocardium is principally responsible for the cardiotoxicity [26]. In addi-
tion, a number of other, non-chemotherapeutical medications are associated with 
DCM, such as cyclophosphamide, phenothiazines, antidepressant drugs, carbon 
monoxide, lead, lithium, pseudoephedrine, ephedrine, cobalt, anabolic steroids, 
hydroxychloroquine, clozapine, and catecholamines [38, 41]. Possible causes of 
toxic cardiomyopathy are summarized in Figure 2.
2.4.1.4 Arrhythmia-induced DCM
Tachycardia-induced cardiomyopathy was described more than 100 years ago 
by Gossage et al. as a reversible form of systolic dysfunction caused by long-lasting 
supraventricular or ventricular arrhythmias [42]. Ongoing rapid atrial or ventricu-
lar pacing may result in systemic changes by neurohormonal activation, character-
ized by reduction in serum sodium, activation of the renin-angiotensin system, 
and an increase of plasma atrial natriuretic peptide, aldosterone, and norepineph-
rine. Abnormal myocardial and cellular remodeling occurs, which may result in 
DCM. Furthermore, epinephrine can also lead to abnormal myocardial and cellular 
remodeling, which further result in biventricular dilatation, decreased contractility, 
and elevation of left and/or biventricular filling pressure [26].
2.4.1.5 Infiltrative diseases
Several, systemic diseases may infiltrate the myocardium and result in 
DCM. Sarcoidosis, iron overload, and amyloidosis represent the most common 
clinical entities. Sarcoidosis is a multisystem inflammatory disease of unknown ori-
gin characterized by non-caseating granulomas in multiple organs. Sarcoidosis can 
progress to a fibrotic stage leading to DCM [26]. In the setting of iron overload, such 
as hereditary hematochromatosis, high blood volume, or parenteral iron infusions, 
Figure 2. 
Reasons for toxic cardiomyopathies.
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DCM may occur due to iron-induced reactive oxygen species with cellular oxidative 
stress and fibrosis [43]. Cardiac amyloidosis is the most common cause of infiltra-
tive cardiomyopathy with poor prognosis. Amyloid is an extracellular tissue deposi-
tion of misfolded amyloid protein-fibrils [44]. Cardiac amyloidosis usually presents 
as a cardiomyopathy with restrictive pathophysiology and can progress to severe 
cardiac dysfunction and to DCM in very advanced stages [26].
2.4.1.6 Endocrine/metabolic disorders
Endocrinologic disorders rarely lead to the phenotype of DCM. Especially thyroid 
hormones have a significant impact on cardiac function and structure via regulation 
and expression of key structural and regulatory genes like myosin heavy chain and 
phospholamban. Therefore, excess or deficiency of triiodothyronine (T3) may lead 
to DCM in a late stage [45]. Growth hormone disorders, pheochromocytoma, and 
Cushing’s disease are also very rare causes of DCM [26, 46]. Furthermore, the litera-
ture names nutritional deficiencies of thiamine (beriberi disease), selenium (Keshan 
disease), and l-carnitine being responsible for DCM [47, 48].
2.4.1.7 Neuromuscular disorders
Neuromuscular disease like Duchenne’s muscular dystrophy, Becker muscular 
dystrophy, and Emery-Dreifuss muscular dystrophy can affect the heart and induce 
DCM. Patients with DCM and muscular dystrophy commonly show X-linked muta-
tions or autosomal recessive inheritance [24]. Further information is summarized in 
the following section on genetic causes of DCM.
2.4.2 Genetic causes of DCM
In up to 30% of the cases, a gene mutation may be identified as the main cause 
of DCM [49]. Thanks to advances in next-generation sequencing technologies more 
than 40 genes have already been identified causing DCM [50]. Most commonly, 
familial DCM is inherited as an autosomal dominant pattern. Autosomal recessive, 
X-linked, and mitochondrial inheritance patterns are less common [24]. Most of 
the genes involved in the development of DCM encode structural elements of the 
cardiomyocytes. Mutations in genes encoding sarcomeric, cytoskeletal, desmo-
somal, nuclear membrane, mitochondrial, and RNA-binding proteins have all been 
linked to DCM [51]. Interestingly, several of the gene mutations linked to autosomal 
dominant DCM encode the same contractile proteins that are also responsible for 
the development of HCM [38]. As well, other affected genes are described in ARVC 
and left ventricular non-compaction cardiomyopathy (NCCM). In the following, we 
will describe the most investigated gene mutations and their consequences on the 
cardiomyocyte functioning.
2.4.2.1 Sarcomere protein location: force generation and transmission
The sarcomere is the contracting unit of the myocyte. The thin filaments of 
the sarcomere emanate from the Z-disc. They consist of filamentous α-actin (gene 
name ACTC 1) and calcium-sensitive troponin-tropomyosin regulatory apparatus 
(encoded by TPM1), which includes the three troponin subunits (encoded by 
TNNT2, TNNC1, and TNNI3) [52, 53]. The thick filament core is formed by the 
β-myosin heavy chain (encoded by MYH7), the molecular motor of the thick fila-
ment, and the myosin-binding protein C (β-MYBPC3) [52, 53]. Titin (encoded by 
TTN), which is the largest human protein, spans the half length of the sarcomere, 
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where it acts as a stretch sensor and myofibril stabilizer. It limits sarcomere stretch 
in early diastole and restores resting sarcomere length after contraction [52, 53]. 
Titin (TTN) mutations are the most prevalent genetic cause of idiopathic DCM 
(15–20%). In fact, DCM patients with TTN mutations have a worse outcome due 
to a higher arrhythmic risk and progressive functional deficits [54]. Mutations in 
human genes encoding protein components of the sarcomere cause either HCM or 
DCM. Deficits of force production and transmission are the two main mechanisms 
that lead to DCM due to sarcomere mutations [55]. Mutations of genes encoding 
myosin proteins (MYH 6, MYH7, and MYBPC3), actin proteins (ACTC 1 and ACTC 
2), and tropomyosin protein (TPM 1) result in alterations of coupling-uncoupling 
mechanisms of actin to myosin [50]. Specifically, TPM1 mutations are associated 
with destabilization of actin interactions and compromise force transmission to 
neighboring sarcomeres. ACTC mutations impair the binding of actin to the Z-disc 
compromising force propagation [55]. Impaired contractile force may also occur 
from troponin mutations. Because troponin molecules modulate calcium-stimu-
lated actomyosin ATPase activity, the mutation causes inefficient ATP hydrolysis 
and decrease contractile strength [55].
2.4.2.2 Cytoskeleton protein location: force transmission and structural integrity
The Z-disc is an electron-dense structure, in which titin and the thin filaments 
anchor. Critical components include α-actinin, which aligns actin and titin from 
neighboring sarcomeres and interacts with muscle LIM protein (MLP encoded by 
CSRP3). Telethonin (encoded by TCAP) is another Z-disc component interacting 
with titin and MLP to support overall sarcomere function. In addition, Cipher/Z-
band alternatively spliced PDZ-motif protein (Cipher/ZASP encoded by LDB3), 
which interacts with α-actinin-2 through a PDZ domain, an abundant protein 
interaction modules that recognize short amino acid motifs of the C-termini of 
target proteins, and couples to protein kinase C (PKC)-mediated signaling via its 
LIM domains [55, 56]. Gene mutations of multiple Z-disc proteins like MLP, car-
diac ankyrin repeat protein (CARP), myopalladin, α-actinin 2, TCAP, and nexilin 
may result in DCM [52]. Cipher/ZASP mutations have been associated to isolated 
left ventricular dilatation or DCM with NCCM phenotype [50]. Metavinculin 
(encoded by VCL) attaches the thin filaments to the plasma membrane and plays 
a key role in force transmission. Gene mutations in metavinculin cause DCM by 
disruption of disc structure and actin-filament organization [55]. The costamere, 
a rib-like structure of the cytoplasmatic and transmembrane proteins, intercon-
nects the cytoskeleton to the plasma membrane and the extracellular matrix. 
Dystrophin and its associated proteins, sacroglycans and dystroglycan, enrich 
at the costamere and protect against contraction-induced injury [52]. The integ-
rity of the dystrophin complex is critical for mechano-transduction and loss of 
function mutations trigger instability of the plasma membrane and myofiber loss. 
This mechanism leads to Duchenne and Becker muscular dystrophy [57]. Desmin, 
another intermediate filament in cardiomyocytes, forms a 3D scaffold that 
extends across the entire diameter of the cardiomyocyte, surrounds the Z-discs 
and interlinks them together and integrates the contractile apparatus with the 
sarcolemma and the nucleus. Desmin helps to sense mechanical stretch and trans-
duces downstream signals from extracellular to the nucleus. In addition, desmin 
plays a crucial role during myogenesis. Inhibition of desmin expression blocks 
myoblast fusion and myotube formation [58]. Mutations in the desmin genes are 
associated with an autosomal dominant skeletal myopathy, cardiac conduction 
block, and DCM [59]. Prevalence of desmin mutations in familial DCM have been 
reported in 1–2% [60].
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2.4.2.3 Desmosomes: cell-cell adhesion and intracellular signaling/mechano-signaling
Desmosomes are organized cell membrane structures that provide functional and 
structural contact between adjacent cells. Mutations in protein components of desmo-
somes like plakoglobin, desmoplakin, and plakophilin-2 can cause syndromic and non-
syndromic ARVC as well as DCM due to disruption of intercellular junction [55, 61].
2.4.2.4 Sarcoplasmic reticulum: calcium homeostasis
Calcium enters the myocyte through voltage-gated L-type Ca2+-channels. This 
triggers the release of calcium from the sarcoplasmic reticulum (SR) via the ryanodine 
receptor 2 (RyR2). At low intracellular calcium concentrations, troponin I and actin 
interactions block actomyosin ATPase activity. With increasing intracellular concen-
tration, calcium binds to troponin C, which releases troponin I inhibition and stimu-
lates contraction. Calcium dissociates from troponin C in cardiac relaxation. Calcium 
concentration decreases by calcium reuptake in the SR through the phospholamban-
regulated cardiac sarcoplasmic reticulum CA2+-ATPase (SERCA2a) [55]. Mutations 
of phospholamban precipitate DCM by altering calcium homeostasis [54]. Specific 
phospholamban mutation R14del is associated with high risk of malignant ventricular 
arrhythmias and end-stage HF. Further, it is described in a phenotype of ARVC [62].
2.4.2.5 Nuclear envelope: maintain structural organization
The nuclear membrane protein complex contains emerin and lamin A/C (LMNA) 
[52, 55]. These two lamina proteins and nesprin-1 are part of the LINC complex that 
links the nucleus to the cytoplasm. Stress signals in the cytoplasm are hypothesized to 
act with the LINC complex, affecting gene expression in the nucleus. The LINC com-
plex is crucial for an appropriate transcriptional response of the cell to mechanical 
stress [52]. Defects in emerin proteins can induce X-linked Emery-Dreifuss muscular 
dystrophy, joint contractures, conduction system disease, and DCM. Dominant 
lamin A/C (encoded by LMNA) mutations exhibit a more cardiac-restricted pheno-
type with fibrofatty degeneration of the myocardium and it is conducting system. 
More than 200 different lamin A/C (LMNA) mutations are associated with inherited 
cardiomyopathy, primarily DCM that may be associated with conduction system 
disease prior to the evidence of ventricular dilatation due to fibrofatty degeneration 
of the myocardium and conducting cells [52, 55]. Other diseases caused by lamin A/C 
mutations are Charcot-Marie-Tooth neuropathy, Dunningan partial familial lipodys-
trophy, progeria and other overlapping syndromes, all known as laminopathies [63].
2.4.2.6 Ion channel
The function of sarcolemmal transmembrane cardiac voltage-gated sodium channel 
is crucial in the generation of cardiac action potentials. Some mutations in the encoding 
gene SCNA5 are implicated in DCM. SCN5A mutations causes high burden of arrhyth-
mias. There are also many allelic variants in SCN5A, including those leading to Brugada 
syndrome, idiopathic ventricular fibrillation (VF), familial atrial fibrillation (AF), left 
ventricular non-compaction cardiomyopathy, and long QT syndrome type III [54, 59, 64].
2.4.2.7 Extracellular matrix-cell-adhesion and signaling
Extracellular matrix proteins such as laminin alpha-4 (LAMA4) and Fukutin 
(FKTN) have been described in relation to DCM. They may lead to DCM phenotype 
by disrupting signaling pathways and modifying cell-surface molecules [50].
The genetic evaluation of DCM is summarized in Table 2.
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Genetic 
evaluation of 
DCM
Gene screening of DCM Genotype correlations of DCM
Sarcomere 
protein related 
genes
• Titin (TNN)
• α-Cardiac actin
(ACTC 1 and ACTC 2)
• α-Tropomyosin 1 (TPM 1)
• Cardiac troponin subtypes
(TNNT2, TNNC1, TNNI3)
• Myosin heavy chains
(MYH 6, MYH7)
• Myosin-binding protein C 
(MYBPC)
• Troponin I-interacting kinase 
(TNNI3K)
• 12–25% of genetic related DCM are associated with titin 
(TTN) mutations
• α-Tropomyosin 1 (TPM 1) mutations are described in 1–2% 
of DCM
• Myosin heavy chain (MYH7)-mutations in 3–4% of DCM
• 3% of DCM are linked to cardiac troponin T (TNNT2) 
mutations
• Gene defects in sarcomere proteins are associated with 
defects in force generation and transmission
• TNNI3K-mutations may cause conduction defects and 
atrial fibrillation
Cytoskeletal 
protein related 
genes: Z-disc
Dystrophin 
complex
Cytoskeleton
• α-Actinin 2 (ACTN 2)
• Muscle LIM protein (MLP)
• Cysteine- and glycine-rich 
protein 3 (CSPR3)
• Telethonin (TCAP)
• Cypher/Z-band (LDB3)
• PDZ LIM domain protein 3
(PDLIM3)
• Cardiac ankyrin repeat 
protein (CARP)
• Myopalladin (MYPN)
• Nexilin (NEXN)
• Metavinculin (VCL)
• Dystrophin (DMD)
• Sacroglycan
(SGCA, SGCB, SGCD, and 
SGCG)
• Desmin (DES)
• Metavinculin (CVL) mutations are related to 1% of DCM
• Dystrophin (DMD) mutations are associated with 
Duchenne/Becker muscular dystrophy
• Sacroglycan (SDC) mutations can cause Limb-girdle-
muscular dystrophy
Prevalence of Desmin (DES) mutations in genetic related 
DCM is about 1–2%, the mutations are often related with 
myofibrillar myopathy, ARCV and cardiac conduction blocks
Desmosomal 
protein related 
genes
• Plakoglobin (JUP)
• Desmoplakin (DSP)
• Desmocollin 2 (DSC2)
• Desmoglein 2 (DSG2)
• Plakophilin-2 (PKP2)
• Mutations in desmosomal genes are frequent in patients 
with advanced DCM undergoing cardiac transplantation
• Desmosomal gene mutations are also linked to ARVC
• Desmoplakin (DSP) causes 2% of genetic related DCM
• Plakoglobin (JUP)-mutations are also associated with 
Naxos syndrome
• Desmocollin 2 (DSC2) mutations may lead to mild 
palmoplantar keratoderma
Sarcoplasmic 
reticulum 
related genes
• Ryanodine receptor 2 (RyR2)
• Phospholamban (PLN)
• SR proteins, Ca-ATPase pump 
(SERCA2a)
• Specific mutations are associated with high risk of malig-
nant ventricular arrhythmias and end-stage heart failure
• Ryanodine receptor 2 (RyR2) correlates with cathecola-
minergic polymorphic ventricular tachycardia and ARVC
• Phospholamban (PLN) mutations can cause ARVC
• Some other genes encoding for sarcoplasmic reticulum and 
cytoplasm related proteins like PTPN11, RAF1 and RIT1 
are also associated with Noonan and Leopard Syndrome
11
Current Pathophysiological and Genetic Aspects of Dilated Cardiomyopathy
DOI: http://dx.doi.org/10.5772/intechopen.83567
2.5 Diagnosis
Establishing the etiology is of great importance as it may influence treatment 
and prognosis of patients with DCM. Beside the conventional clinical tools, modern 
imaging and genetic tools are available to elucidate and ensure the correct diagno-
sis. The recently published statement for the diagnostic workup on DCM from the 
ESC working group on myocardial and pericardial diseases recommend the follow-
ing steps: first the diagnostic evaluation should be start with in-depth personal and 
family history, followed by physical examination, an electrocardiogram (ECG), and 
echocardiography [8]. These steps often sufficiently differentiate between acquired 
and familial DCM. If there is no suspicion of an acquired DCM and if ‘red flags’ are 
recognized, the second-level diagnostic work-up should be added. ‘Red flags’ are 
defined as signs and suspicion on a specific etiology. Biochemical analyses, cardiac 
magnetic resonance imaging (CMR), endomyocardial biopsy (EMB), and genetic 
testing are recommended in a second step. However, the patient’s age plays a crucial 
role in the decision-making during the diagnostic procedure and should be rated 
against the potential benefit of dedicated investigations. The detailed diagnostic 
workup and possible red flags are presented in Table 3.
2.6 Screening
In common, DCM is a slowly progressive disease and screening is essential 
for an early diagnosis of asymptomatic family members. Currently, screening all 
first-degree family members of patients with genetic proven or non-genetic forms 
of DCM with a positive family history is recommended. The screening comprises 
Genetic 
evaluation of 
DCM
Gene screening of DCM Genotype correlations of DCM
Nuclear 
envelope and 
nucleus protein 
related genes
• Emerin (EMD)
• Lamin A/C (LMNA)
• EMD mutations can lead to X-linked Emery-Dreyfuss 
muscular dystrophy, joint contractures and conduction 
system disease
• Prevalence of genetic-related DCM due to LMNA mutation 
is described in 4–8%
• LMNA-related heart failure is often more resistant to heart 
failure therapy and has a high risk for arrhythmias and 
sudden cardiac death
• Mutations in LMNA can cause a severe and progressive 
DCM and can also lead to Charcot-Marie-Tooth neuropa-
thy, Dunningan partial familial lipodystrophy, Emery-
Dreyfuss muscular dystrophy and progeria
Ion channel 
protein related 
genes
• Sodium channel, voltage-
gated, type V, alpha subunit 
(SCNA5)
• Potassium channel (KCNQ1)
• SCN5A mutations account for 2–3% of DCM, muta-
tions are associated with Brugada syndrome, Long QT 
syndrome, atrial fibrillation and conduction defects
• KCNQ1 mutations may induce atrial fibrillation, Long QT 
1, Short QT1 and Jervell and Lange-Nielsen syndrome
Extracellular 
matrix protein 
related genes
• Laminin alpha-4 (LAMA4)
• Fukutin (FKTN)
• Extracellular matrix protein relation has been described 
to DCM
• FKTN and LAMA2 mutations can also cause congenital 
muscular dystrophy
Table 2. 
Genetic aspects of dilated cardiomyopathy.
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physical examination, 12-lead ECG and transthoracic echocardiography as well as 
measurement of CK levels. The CK levels may help to identify subclinical skeletal 
muscle abnormalities and to provide supportive evidence for the presence of an 
inherited myopathy. If DCM is suspected in first-degree relatives, the screening 
should be repeated anually. Otherwise, asymptomatic first-degree relatives should 
be rescreened at three- to five-year intervals because of possible late onset of DCM 
phenotype [21].
Diagnostic tool Look for Red flags for specific disorders
Personal and familial 
history
Degree of symptoms
Travel history
Inheritance pattern
Toxin exposition Involvement of other 
organs
Intellectual and sensorineural disabilities
Muscle weakness
Myotonia
Gait disturbances
Skin abnormities, for example, 
hyperpigmentation and palmoplantar 
keratoderma, butterfly-shaped face rash
Woolly hair
Electrocardiogram Low P-wave amplitude
Atrioventricular block
Repolarization disorders with non-coronary 
distribution
Low QRS amplitude
Bundle branch block
Long QTc
Ventricular arrhythmias
24 h electrocardiogram Relevant brady- and tachyarrhythmias Relevant tachyarrhythmias
24 h ambulatory blood 
pressure monitoring
Exclude persistent hypertension
Biochemistry Blood count
Electrolytes
Renal function
Cardiac biomarkers
TSH
HbA1c
Serum iron, ferritin and 
electrophoresis
Urine chemistry and proteinuria
Serum free light chains
HIV and hepatitis serology
Other specific serology tests in 
accordance symptoms and clinical 
suspicion
High levels of creatine kinase
Myoglobinuria
Increased serum iron & ferritin levels
Leucopenia or neutropenia
Free light chains for amyloidosis
Diabetes and lactatacidosis
Thyroid disorders
Infectious etiologies
Echocardiography Ventricular dilatation
Valve diseases
Right ventricular pathologies
Left ventricular hypertrabecularisation
Segmental dysfunction with noncoronary 
distribution
Coronary angiography Exclude coronary artery disease
CMR Late Gadolinium Enhancement
Intramyocardial edema
Intramyocardial iron deposit
Right ventricular morphology
Molly sequence
Patchy or inferobasal late gadolinium 
enhancement (LGE) distribution
“Midwall sign” septal wall LGE distribution
EBM Giant cell myocarditis
Genetics Screening familial DCM
Table 3. 
Diagnostic workup and possible red flags in dilated cardiomyopathy.
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2.7 Therapy
Specific treatment is applicable in syndrome associated DCM, for example, 
infectious etiologies and infiltrative disorders. However, specific treatment is not 
available for most DCM patients. Therefore, the therapy focuses on improvement 
of clinical symptoms as well as on the control of disease progression and potential 
complications such as sudden cardiac arrest.
2.7.1 Heart failure treatment
Guidelines recommend the following treatment for acute HF, not including non-
cardiogenic shock: oxygen, non-invasive ventilation (NIV), intravenous diuretics 
(20–40 mg bolus furosemide at admission), and intravenous nitrates. Intravenous 
nitrates have long been described to improve hemodynamic and dyspnea in HF 
patients by many ways: decrease in systemic blood pressure and left ventricular 
afterload, substantial reduction preload and therefore of in right and left ventricular 
filling pressure, an increase in cardiac output, and little or no change in heart rate 
[65]. Improvement in cardiac output by intravenous nitrates is mostly related to the 
reduction in left ventricular afterload, but is also influenced by a decrease in pulmo-
nary vascular resistance, improvement in myocardial oxygenation, and a reduction 
of mitral regurgitation. Administration of inotropes and/or vasopressors is recom-
mended in patients with signs of low cardiac output [66]. However, application of 
inotropes and/or vasopressors is associated with an increased long-term mortality 
risk [67–69]. Additional treatment includes the optimal dosing of angiotensin-
converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB). ACEI 
have been shown to reduce cardiovascular mortality and prevent rehospitalization 
in patients with HF in two key randomized controlled trails (CONSENSUS and 
SOLVD-Treatment) [70]. Likewise, ARB improve long-term outcome in HF patients 
[71]. Another essential component of HF therapy is spironolactone. The RALES 
study has shown a reduction in mortality after addition of 25 mg of spironolactone 
to the standard treatment in HF patients with an LVEF <35% [72]. The international 
guidelines recommend spironolactone in all patients presenting with moderate to 
severe HF symptoms. In the PARADIGM-HF trial, the use of angiotensin receptor-
neprilysin inhibitor (ARNI) (sacubitril/valsartan) showed a reduction of the com-
posite endpoint of cardiovascular death or HF hospitalization by 20% compared with 
enalapril alone in symptomatic HF patients with reduced LVEF [73]. These study 
results are implemented in the updated ACC/AHA/HFSA guidelines on management 
of HF, which recommend to replace ACEI or ARB by sacubitril/valsartan in patients 
with reduced LVEF and ongoing symptoms [74]. Betablockers reduce mortality in HF 
patients even without reduced ejection fraction as has been demonstrated by multi-
center placebo-controlled studies [75–77]. Because of the negative inotropic effect of 
betablockers, patients should not be treated in the very acute presentation with signs 
or symptoms of decompensation and initial doses should be low. Long-term goal is a 
heart rate below 70 bpm in sinus rhythm. If this is not obtainable with the maximum, 
or maximum tolerated dose of betablockers, the current European heart failure 
guidelines recommend the addition of Ivabradine [66]. In addition to pharmacologi-
cal medication cardiac resynchronization therapy (CRT) has been shown to improve 
cardiac performance, to reduce symptoms, morbidity, and mortality [78, 79].
2.7.2 Anticoagulation
The role of anticoagulation in DCM with sinus rhythm is unclear [80]. The 
prospective randomized trials were either underpowered or with a too short 
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follow-up. At present, there are no trial data to guide anticoagulant treatment 
regime in DCM. Due to two studies (WATCH and WARCEF trial) showing a slight 
advantage of warfarin over aspirin, anticoagulation with warfarin is advised in 
patients with a history of thromboembolism or evidence of intracardiac thrombus 
[81, 82]. Current ACC/AHA HF guidelines do not recommend anticoagulation in 
reduced left ventricular function and sinus rhythm without prior thromboem-
bolic events or known cardioembolic source [83]. Studies testing the non-vitamin 
K antagonist oral anticoagulants (NOACs) in patients with reduced left ventricu-
lar function are currently ongoing. In DCM patients with documented AF, oral 
anticoagulant is recommended with CHA2DS2-VASc score ≥ 2, as a class I indica-
tion and in men with a CHA2DS2-VASc score of 1 as class IIa with level of evidence 
B [66, 77, 83, 84].
2.7.3 Arrhythmias
The most common arrhythmia in DCM is AF, which increases the risk of 
thromboembolic complications, impairs cardiac function and worsening HF 
symptoms. Therefore, evaluation of rate control and anticoagulation in order to 
preserve LV-function and prevent thromboembolic events is crucial. In the acute 
setting betablockers, digoxin and their combination may be used to control ven-
tricular rate. In the chronic stage, rhythm control has been shown to be superior 
to rate control alone in reducing mortality [85]. Because of the commonly reduced 
left ventricular function, the only therapeutic option is type III antiarrhythmic 
drug such as amiodarone. Alternatively, electrical cardioversion can be performed. 
Recently, the CASTLE-AF study demonstrated the superiority of AF catheter 
ablation in certain patients with HF as compared to medical therapy. The ablation 
was associated with a significantly lower rate of death and hospitalization for 
worsening HF [86]. DCM patients may suffer from ventricular arrhythmias (VA), 
which are mainly caused by myocardial damage, fibrosis and/or loss of cell-to-cell 
conjunctions, that are described by three mechanisms: reentry, trigger activity, 
and automatism [87]. Monomorphic ventricular tachycardias (VTs) are frequently 
induced by macro-reentry mechanism, which is best treated by ablation. The 
main trigger mechanisms are electrolyte imbalance, mostly secondary to diuretic 
treatment, antiarrhythmic drugs, and bradycardia. The therapeutic options are a 
combination of antiarrhythmic drugs like betablockers and type III antiarrhyth-
mics and/or implantation of an implantable cardioverter defibrillator (ICD). The 
indications for ICD treatment are described later [4].
2.8 Prognosis and risk stratification
Although there has been a significant improvement in prognosis of DCM 
patients over the last decades, mortality is still high. The prognosis is mainly influ-
enced by HF symptoms and more relevant by the appearance of VTs. Survival data 
of adults with DCM have shown a one-year mortality of 25–30% and a 50% survival 
at 5 years. Sustained VT or VF presents the main cause for SCD, which occurs in up 
to 12% of DCM patients [4, 88]. In general, the prevalence of sustained VT (mono-
morphic or polymorphic) is estimated as less than 5% [89]. Recently, the Pediatric 
Cardiomyopathy Registry presented a 5-year incidence rate of SCD in children with 
DCM of 3% [90]. An age at diagnosis below 14 years, LV dilation, and posterior wall 
thinning were identified as the most important risk factors. In contrast, the mortal-
ity in adults is mostly associated with age and male gender, reduced New York Heart 
Association (NYHA) functional class, impaired LVEF, and the presence of specific 
cardiac biomarkers as well as myocardial fibrosis in CMR [91–94]. Furthermore, 
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genetic aspects play an important role for detection of high-risk patients. Most 
commonly the pathogenic mutation in the lamin A/C (LMNA) gene is associated 
with atrial and ventricular arrhythmias. LMNA mutation has been identified as the 
most malignant and penetrant condition with worse outcomes compared to other 
forms of DCM [95]. Beside risk models such as the Seattle Heart Failure Model for 
the prediction of prognosis in the general population of HF patients, there exist no 
specific risk tools for DCM patients [96]. For the identification of high-risk DCM 
patients, a personalized and precise approach is required (Table 3). This should 
include the personal and familial history, measurement of LVEF, detailed search 
for VA and proof of fibrosis using CMR. Other promising approaches are expected 
to be helpful in decision-making in high-risk DCM patients, determination of 
microvolt T-wave alternans analysis and detection of autonomic dysfunction using 
nuclear imaging. In addition, detection of LMNA gene mutation has been described 
to identify the high-risk DCM population. However, all these approaches need 
further research.
2.9 Prevention of sudden cardiac death
The most effective therapy of malignant VTs and thus prevention of SCD in 
DCM patients is the implantation of an ICD. Current ESC guidelines recommend 
the implantation of a defibrillator in patients who experienced VT or VF (secondary 
prevention of sudden cardiac death), as well as in high risk patients for primary 
prevention. The latter are patients with symptomatic HF NYHA class II–III and 
LVEF ≤35% after ≥3 months of optimal medical therapy who are expected to 
survive for at least 1 year [97]. Similarly, the American College of Cardiology and 
American Heart Association guidelines recommend ICD therapy in patients with 
LVEF ≤35% due to prior myocardial infarction (MI), at least 40 days post-MI, or 
non-ischemic DCM and NYHA class II or III [98]. However, existing guidelines 
lack sensitivity and specificity for the selection of patients with DCM for primary 
prevention ICD implantation. A recently presented meta-analysis by Golwala 
et al. has demonstrated a 23% reduction in all-cause mortality with ICD therapy 
compared with optimal medical therapy alone (HR, 0.77; 95% CI, 0.64–0.91) [99]. 
Although ICD implantation seems to be the best possible option for SCD preven-
tion in DCM, there remain potential complications. Inappropriate shocks, risk of 
infection, device or lead replacement have to be considered and discussed in detail 
before an ICD is implanted.
3. Conclusion
DCM includes a heterogeneous group of myocardial and systemic conditions 
causing left ventricular dilatation and dysfunction. DCM is one of the most 
common cardiomyopathies worldwide. Yet, the real prevalence is unknown. The 
etiology contains non-genetic (e.g. myocarditis, peripartum, toxics, arrhyth-
mia, infiltrative etiologies, endocrine, nutritional, and neuromuscular) and 
genetic causes. Literature on genetic mutations being responsible for DCM has 
increased exponentially. Today, up to 30% of the DCM cases are described to 
be caused by a gene mutation, the majority of which occur in autosomal genes 
that encode for a wide range of proteins of the cardiomyocyte’s structural 
elements. Mutations in genes encoding sarcomeric, cytoskeletal, desmosomal, 
nuclear membrane, mitochondrial, and RNA-binding proteins have all been 
linked to DCM. However, the most common mutations occur in genes encod-
ing sarcomeric proteins and in genes related to the nuclear envelope and the 
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cytoskeleton. Therefore, the diagnostic workup of DCM should involve the 
clinical tools as well as imaging and gen-technologies. Specific treatment is only 
available for syndrome-associated DCM. The majority of the DCM patients are 
treated for HF symptoms, prevention of thromboembolic events, and malign 
arrhythmias. The prognosis of DCM patients is variable and depends on multi-
ple risk factors. Some, for example, LVEF and NYHA functional class are known 
for years as risk factors of SCD, others need further research before they can be 
established in clinical routine.
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Acronyms and abbreviations
ACEI angiotensin converting enzyme inhibitors
AF atrial fibrillation
AIDS acquired immune deficiency syndrome
AHA American Heart Association
ARB angiotensin receptor blockers
ARVC arrhythmogenic right ventricular cardiomyopathy
CAD coronary artery disease
CARP cardiac ankyrin repeat protein
CK creatine kinase
CMR cardiac magnetic resonance imaging
DCM dilated cardiomyopathy
DES desmin
ECG electrocardiogram
EMB endomyocardial biopsy
ESC European Society of Cardiology
HCM hypertrophic cardiomyopathy
HF heart failure
HIV human immundeficiency virus
ICD implantable cardioverter defibrillator
IDC idiopathic dilated cardiomyopathy
ISFC International Society and Federation of Cardiology
LAMA4 laminin alpha-4
LINC links the nucleus to the cytoplasm
LMNA lamin A/C
LVEF left ventricular ejection fraction
MI myocardial infarction
MLP muscle LIM protein
MYH myosin proteins
NCCM non-compaction cardiomyopathy
NIV non-invasive ventilation
NOAC non-vitamin K antagonist oral anticoagulant
NYHA New York Heart Association
PPCM peripartum cardiomyopathy
RCM restrictive cardiomyopathy
RNA ribonucleid acid
RyR2 ryanodine receptor 2
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WHO World Health Organization
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